



## Please Fax Completed Form To: 888-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)
Please Send a Copy of The Patient's Up-to-Date Clinical Notes

PATIENT INFORMATION (Complete or Fax Existing Chart)		PRESCRIBER INFORMATION				
Name: DOB:		Prescriber Name:				
Address:		State License:				
City, State, Zip:		NPI #:Tax ID:				
Phone: Alt. Phon	ne:	Address:				
Email: SS#:		City, State, Zip:				
Cender:			Fax:			
Allergies:		Office Contact:	Phone:			
INSURANCE INFORMATION – AND – Send a copy of the patient's prescription/insurance cards (front & back)						
Primary Insurance:		Secondary Insurance (If Applicable):				
Plan #:		Plan #:				
Group #:		Group #:				
RX Card (PBM):		RX Card (PBM):				
BIN: PCN:	E	BIN: PCN:				
CLINICAL INFORMATION						
G43.711 Chronic migraine without aura, intractable, with status migrainosus G43.111 Migraine with aura, intractable, with status migrainosus						
☐ G43.119 Migraine with aura, intractable, without status migrainosus ☐ Other ICD-10 Code:						
Date of Diagnosis:	Average number of r	migraine days over the last 3	months:			
Previous Migraine Medications:						
VYEPTI® ORDERS						
Prescription type:   New start   Restart	t   Continued therapy Total De	oses Received:	Date of Last Injection/Infusion:			
Medication	Dose		Refills			
□ Vyepti (eptinezumab-jjmr)	☐ 100 mg dose (1-100mg vial)		1 vial (100mg) Refills:			
	□ 300 mg dose (3-100mg vial) □ 3 vials (300mg) Refills:					
Administer the diluted Vyepti solution by IV with a 0.2 or 0.22 μm in-line or add-on sterile filter. Infuse over approximately 30 minutes. Flush the line with 20 mL or 0.9% Sodium Chloride Injection, USP. Repeat dose every 3 months.						
Other:	jeedon, oor . Nepeut dose every or	nontris.				
Pre-Medication	Dose/Strength		Directions			
☐ Acetaminophen	☐ 500mg ☐ Take 1-2 tablets PO prior to infus		rior to infusion or post-infusion as directed			
☐ Diphenhydramine	☐ 25mg IV/PO	5mg IV/PO				
	☐ 50mg IV/PO	☐ Inject contents of 1 vial IV prior to infusion or as directed				
☐ Methylprednisolone	☐ 40mg ☐ 100mg ☐ Inject contents of 1 vial IV prior to		ial IV prior to infusion or as directed			
	☐ 125mg	☐ Other: Inject 100mg IV 30 minutes prior to infusion				
INFUSION REACTION ORDERS						
Mild reaction protection						
Mild reaction protocol:	r pruritus					
Mild reaction protocol:  ☑ Diphenhydramine 25mg IV, one time, for If symptoms worsen, see orders for moderal.						

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.





## Please Fax Completed Form To: 88-898-9113

Please Send a Copy of The Patient's Insurance Cards (Front & Back)
Please Send a Copy of The Patient's Up-to-Date Clinical Notes

oximes Acetaminophen 650mg PO, one time, for pyrex	tia or rigors						
oximes Diphenhydramine 50mg IV, one time, for prurit	tus or urticaria						
oximes Methylprednisolone 125mg IV, one time, for re	espiratory or neurologic syr	nptoms					
If symptoms worsen, see interventions for severe r	reactions						
Severe reaction protocol: (Call 911 if initiated):							
☑ Titrate oxygen via continuous flow per nasal cannula or face mask to maintain spO2 of greater than ninety-five percent (>95%)							
☐ Diphenhydramine 50mg IV, one time, for respiratory symptoms, edema, or anaphylaxis							
oximes Methylprednisolone 125mg IV, one time, for re	spiratory symptoms, eden	na, or anaphylaxis					
oxtimes Sodium Chloride 0.9% 500mL IV over 30-60 mir	n, one time, for cardiovasc	ular symptoms					
oximes Epinephrine 0.3mg/0.3mL IM into mis-anterola	teral aspect of thigh of ana	aphylaxis, may repeat x1	in 5-15 minutes if symptoms	are not resolved or			
worsen							
FLUSHING & LOCKING ORDERS							
Flushing Protocol (>66lbs/33kg)							
PIV and Midline:		Implanted Port, PICC, Tunneled Catheter, and Non-tunneled Catheter:					
oximes 0.9% Sodium Chloride 2-5mL IV flush before and after each infusion							
Locking Protocol (>66lbs/33kg)							
PIV and Midline:	PICC:		Implanted Port, Tunneled	Catheter, and Non-			
□ Heparin Sodium 10 units/mL 1mL IV final	□ Heparin Sodium 10 units/mL 3mL IV final		tunneled Catheter:				
flush post normal saline flush	flush post normal saline flush		☑ Heparin Sodium 100 units/mL 3-5mL IV final				
** May substitute Dextrose 5% in Water, or alternative	for 0.98 Sodium Chlorida w	then indicated due to incon	flush post normal saline fl				
	, for 0.5& 30dium emoride, w	men mulcated due to moon	ipationity with medications of in	giiiuseu			
SIGNATURE							
We hereby authorize Talis Healthcare LLC to prov	vide all supplies and addition	onal services (nursing/pa	tient training) required to pro	vide and deliver the			
medicine as prescribed in this referral.							
V			Dato	Droccribor			

To ensure payment by insurance carrier, please include supporting clinical documentation for specified ICD 10 Code, demographic, and insurance information along with faxed order. Initial appointment will be verified upon insurance approval.

Signature

CONFIDENTIALITY STATEMENT: This facsimile and documents accompanying this transmission contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender at the address and telephone number set forth herein and arrange for return or destruction of the material. In no event should such material be read by anyone other than the named addressee, except by express authority of the sender to the named addressee.